Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6004 with 5-FU and Cetuximab in Head and Neck Cancer
NCT03109158Phase 2Completed
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of NK211 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by NanoCarrier Co., Ltd.. Started Mar 2017; status: completed.
02
Drugs
NK211
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03109158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109158.